

<b>Booked on</b>	27/02/2018	<b>Patient Id</b>	011802270288	<b>Printed on</b>	22/03/2018
<b>Name</b>	Mrs Maya Dina Nath	<b>Age</b>	66 Years	<b>Sex</b>	F
<b>Ordering Physician</b>	Dr Amit Verma Max Hospital				


## Germline Mutation Analysis Panel for Cancer Predisposition

Sample Information
Sample Type: Blood
Clinical Indications
Diagnosed with breast cancer (age at diagnosis: 66 years).
Test Details
Inherited cancer: All 86 genes in the germline cancer predisposition panel (listed in attached Appendix) were assessed for any key and incidental findings in the genes recommended by ACMG (American College of Medical Genetics and Genomics).
Results
<b>Negative</b> (uninformative) for disease causing or likely disease-causing variants in the genes tested in this cancer.
Interpretation
<ul style="list-style-type: none"> <li>This individual does not carry any germline pathogenic (disease-causing) or likely pathogenic (likely disease causing) variant in the genes associated with hereditary breast and ovarian cancer predisposition.</li> <li>The probability that a pathogenic or likely pathogenic variant, inclusive of SNVs (single nucleotide variants), indels (small deletions, duplications or insertions) and structural variants (large deletions/duplications or complex rearrangements), in the tested genes was not detected by the test is extremely small and is close to 0%. Additional testing using MLPA (Multiplex Ligation-dependent Probe Amplification) based test for detection of large deletion/duplication variants can further reduce this probability.</li> <li>A negative test result reduces but does not exclude the possibility that this individual's personal history of cancer has a genetic cause, as it may be due to variation in a genomic region not covered by the test, such as weakly associated genes or due to poorly understood polygenic variants.</li> </ul>
Recommendations
Genetic counseling is recommended for the patient and other family members. The physician can request reanalysis of the data, and this is recommended on an annual basis. Data from this test can be reassessed for the presence of any variants that may be newly linked to established genes or to newly identified disorders since the date of this report that could be associated with the patient's phenotype, based on currently available scientific information. A charge may apply for reanalysis.
For further details, kindly contact: <a href="mailto:contact@molq.in">contact@molq.in</a>
Limitations of Gene Coverage
For each test gene, the fraction of the gene covered by less than 20 reads is indicated below.

Gene	HGMD variants not covered	% of Coding Region under covered
<i>BRIP1</i>	2 / 75	0.37 %
<i>MSH2</i>	8 / 686	0.82 %
<i>NF1</i>	3 / 1709	0.05 %
<i>PTEN</i>	1 / 406	0.74 %
<i>MLH1</i>	1 / 700	0.18 %
<i>MSH6</i>	1 / 363	1.15 %
<i>PMS2</i>	1 / 118	0.27 %

\*\*\*\*End of the report\*\*\*\*

Report Released by:



**Dr. Jatinder Kaur, PhD**

**Head, Molecular Biology & Genomics**

## Appendix

### Test Description

The MolQ Germline Cancer Predisposition Panel include genes associated with both common (e.g., breast, colorectal) and rare cancers. The test involves preparation of a target sequence enrichment based library from the patient's genomic DNA (gDNA) using Illumina's Nextera's technology. The panel covers 86 unique genes and includes variation coverage for all coding exons (>97%) and essential splice sites.

### Genes evaluated: 86 genes

*AIP, ALK, APC, ATM, BLM, BMPRIA, BRCA1, BRCA2, BRIP1, BUB1B, CDC73, CDH1, CDK4, CDKN2A, CEP57, CHEK2, CYLD, DDB2, DICER1, DIS3L2, EGFR, EPCAM, ERCC2, ERCC3, ERCC4, ERCC5, EXT1, EXT2, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FH, FLCN, GPC3, HNF1A, HRAS, KIT, MAX, MEN1, MET, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, NSD1, PALB2, PMS1, PMS2, PRF1, PRKARIA, PTCH1, PTEN, RAD51C, RAD51D, RB1, RECQL4, RET, SBDS, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCB1, STK11, SUFU, TP53, TSC1, TSC2, VHL, WRN, WT1, XPA, XPC.*

### Methodology

**Sample preparation:** Genomic DNA from saliva, blood or any other standard tissue source is used to make the library. "Nextera" library preparation uses a transposon based shearing of the genomic DNA and allows the DNA to be "tagmented" (fragmented and tagged simultaneously in the same tube). Limited cycle PCR step allows the incorporation of adaptors, platform-specific tags and barcodes to prepare the DNA sequencing libraries.

**Target Enrichment:** Approximately 500 ng of each library is used for target enrichment. For this panel, up to 12 libraries can be combined into a single tube and set up for enrichment, to generate adequate coverage on a Miseq sequencer. Two simultaneous enrichment steps are performed to optimize the pull down of regions of interest using target specific probes.

**Sequencing Details:** Sequencing is performed using a standard v2 kit on Illumina Miseq with the expected data output of 4.0-5 GB. For this panel, the output size is 0.253 MB, optimum cluster density to be achieved during sequencing is 750-1000 clusters/mm<sup>2</sup>.

### Analysis

The trimmed fastq files were generated using MiSeq Reporter from Illumina. The reads were aligned against the whole genome build hg19. Five bas e-pairs from the 3' end of the reads were trimmed, as were 3' end bases with quality below 10. Reads which had length less than 25bp after trimming were not considered for alignment. A maximum of 5 matches of alignment score at least 90% were computed. The reads were realigned using the local realignment tool. Reads that failed vendor QC, reads with average quality less than 20, reads with ambiguous characters were all filtered out. The NGS variant caller was used to detect variants at locations in the target regions covered by a minimum of 10 reads with at least 2 variants reads. Variants with a decibel score of at least 50 were reported.

### Limitations

This test is based on a research protocol. At present FDA has determined that clearance or approval is not necessary for this test. Variants that have not been confirmed by an independent analysis could represent technical artifacts. Some types of genetic abnormalities may not be detectable by this test. It is possible that the genomic region where a disease causing variation exists in the proband was not captured using the current technologies and therefore was not detected. Additionally, it is possible that a particular genetic abnormality may not be recognized as the underlying cause of the genetic disorder due to incomplete scientific knowledge about the function of all genes in the human genome and the impact of variants on those genes. The quality of sequencing varies between regions. Many factors such as homopolymers, GC-rich regions etc. influence the quality of sequencing. This may result in an occasional error in sequence reads.